299 related articles for article (PubMed ID: 28331826)
41. Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features presenting as ground-glass opacities on CT.
Mirtcheva RM; Vazquez M; Yankelevitz DF; Henschke CI
Clin Imaging; 2002; 26(2):95-100. PubMed ID: 11852215
[TBL] [Abstract][Full Text] [Related]
42. Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications.
Lee HY; Lee KS
J Thorac Imaging; 2011 May; 26(2):106-18. PubMed ID: 21508733
[TBL] [Abstract][Full Text] [Related]
43. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
[TBL] [Abstract][Full Text] [Related]
44. Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
Zhang Y; Deng C; Ma X; Gao Z; Wang S; Zheng Q; Xia G; Wen Z; Han H; Fu F; Liu Q; Hu H; Li Y; Wong KK; Chen H
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2411-2417. PubMed ID: 32356178
[TBL] [Abstract][Full Text] [Related]
45. CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.
Rizzo S; Petrella F; Buscarino V; De Maria F; Raimondi S; Barberis M; Fumagalli C; Spitaleri G; Rampinelli C; De Marinis F; Spaggiari L; Bellomi M
Eur Radiol; 2016 Jan; 26(1):32-42. PubMed ID: 25956936
[TBL] [Abstract][Full Text] [Related]
46. Management for Residual Ground-Glass Opacity Lesions After Resection of Main Tumor in Multifocal Lung Cancer: A Case Report and Literature Review.
Cheng B; Deng H; Zhao Y; Zhu F; Liang H; Li C; Zhong R; Li J; Xiong S; Chen Z; Liang W; He J
Cancer Manag Res; 2021; 13():977-985. PubMed ID: 33568943
[TBL] [Abstract][Full Text] [Related]
47. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
48. Pathological features and prognostic implications of ground-glass opacity components on computed tomography for clinical stage I lung adenocarcinoma.
Katsumata S; Aokage K; Ishii G; Hoshino H; Suzuki J; Miyoshi T; Tane K; Samejima J; Tsuboi M
Surg Today; 2021 Jul; 51(7):1188-1202. PubMed ID: 33745094
[TBL] [Abstract][Full Text] [Related]
49. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.
Lee HJ; Kim YT; Kang CH; Zhao B; Tan Y; Schwartz LH; Persigehl T; Jeon YK; Chung DH
Radiology; 2013 Jul; 268(1):254-64. PubMed ID: 23468578
[TBL] [Abstract][Full Text] [Related]
50. Pure ground-glass opacity on chest computed tomography: predictive factors for invasive adenocarcinoma.
Moon Y; Sung SW; Lee KY; Sim SB; Park JK
J Thorac Dis; 2016 Jul; 8(7):1561-70. PubMed ID: 27499944
[TBL] [Abstract][Full Text] [Related]
51. The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection.
Moon Y; Lee KY; Park JK
J Thorac Dis; 2017 Oct; 9(10):3782-3792. PubMed ID: 29268386
[TBL] [Abstract][Full Text] [Related]
52. [Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].
Hu Y; Yang X; Nie L; Zhao D; An J; Li B
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):337-342. PubMed ID: 32336065
[TBL] [Abstract][Full Text] [Related]
53. Focal ground-glass opacity detected by low-dose helical CT.
Nakata M; Saeki H; Takata I; Segawa Y; Mogami H; Mandai K; Eguchi K
Chest; 2002 May; 121(5):1464-7. PubMed ID: 12006429
[TBL] [Abstract][Full Text] [Related]
54. The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma.
Wang H; Guo H; Wang Z; Shan B; Lin J
Biomed Res Int; 2019; 2019():9643836. PubMed ID: 30956990
[TBL] [Abstract][Full Text] [Related]
55. Ground glass opacities management in the lung cancer screening era.
Migliore M; Fornito M; Palazzolo M; Criscione A; Gangemi M; Borrata F; Vigneri P; Nardini M; Dunning J
Ann Transl Med; 2018 Mar; 6(5):90. PubMed ID: 29666813
[TBL] [Abstract][Full Text] [Related]
56. Small (≤ 20 mm) ground-glass opacity pulmonary lesions: which factors influence the diagnostic accuracy of CT-guided percutaneous core needle biopsy?
Li Y; Yang CF; Peng J; Li B; Zhang C; Yu JH
BMC Pulm Med; 2022 Jul; 22(1):265. PubMed ID: 35799223
[TBL] [Abstract][Full Text] [Related]
57. Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma.
Sugano M; Shimizu K; Nakano T; Kakegawa S; Miyamae Y; Kaira K; Araki T; Kamiyoshihara M; Kawashima O; Takeyoshi I
Oncol Rep; 2011 Nov; 26(5):1205-11. PubMed ID: 21811765
[TBL] [Abstract][Full Text] [Related]
58. Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule.
Kim TJ; Goo JM; Lee KW; Park CM; Lee HJ
Lung Cancer; 2009 May; 64(2):171-8. PubMed ID: 18799230
[TBL] [Abstract][Full Text] [Related]
59. A computerized tomography-based radiomic model for assessing the invasiveness of lung adenocarcinoma manifesting as ground-glass opacity nodules.
Zhu M; Yang Z; Wang M; Zhao W; Zhu Q; Shi W; Yu H; Liang Z; Chen L
Respir Res; 2022 Apr; 23(1):96. PubMed ID: 35429974
[TBL] [Abstract][Full Text] [Related]
60. Management of multiple pure ground-glass opacity lesions in patients with bronchioloalveolar carcinoma.
Kim HK; Choi YS; Kim J; Shim YM; Lee KS; Kim K
J Thorac Oncol; 2010 Feb; 5(2):206-10. PubMed ID: 19901852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
